Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation

• Published in: Journal of thrombosis and thrombolysis Vol. 48; no. 3; pp. 500 - 505
• Main Authors: Gruca, Martin M., Li, Yun, Kong, Xiaowen, DeCamillo, Deborah, Kline-Rogers, Eva, Ali, Mona A., Kaatz, Scott, Dahu, Musa, Froehlich, James B., Barnes, Geoffrey D.
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.10.2019; Springer Nature B.V
• Subjects: Aged; Anticoagulants; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; Cardiac arrhythmia; Cardiology; Creatinine; Creatinine - blood; Creatinine - pharmacokinetics; Drug Monitoring - methods; Drug Monitoring - standards; Factor Xa Inhibitors - adverse effects; Factor Xa Inhibitors - therapeutic use; Female; Fibrillation; Health risk assessment; Hematology; Humans; Kidney Diseases - complications; Male; Medicine; Medicine & Public Health; Michigan; Middle Aged; Population studies; Quality control; Renal function; Retrospective Studies; Stroke; Stroke - prevention & control; Michigan; Creatinine; Drug monitoring; Kidney diseases; Atrial fibrillation; Factor Xa inhibitors
• ISSN: 0929-5305; 1573-742X
• DOI: 10.1007/s11239-019-01883-0

Guidelines and experts note that patients with atrial fibrillation require regular renal function monitoring to ensure safe use of direct oral anticoagulants (DOACs). Insufficient monitoring could lead to inappropriate dosing and adverse events. Our objective was to describe the frequency of insufficient creatinine monitoring among patients on DOACs, and to describe clinical factors associated with insufficient monitoring. We hypothesized that renal impairment would be associated with insufficient monitoring. A retrospective cohort study was performed with data from the Michigan Anticoagulant Quality Improvement Initiative. Patients were included if they initiated DOAC therapy for stroke prevention related to atrial fibrillation, remained on therapy for ≥ 1 year, and had baseline creatinine and weight measurements. Creatinine clearance (CrCl) was calculated via Cockcroft-Gault equation. Our outcome was the presence of insufficient creatinine monitoring, defined as: < 1 creatinine level/year for patients with CrCl > 50, or < 2 creatinine levels/year for patients with CrCl ≤ 50. Multivariable analysis was done via logistic regression. Study population included 511 patients. In overall, 14.0% of patients received insufficient monitoring. Among patients with CrCl > 50, 11.5% had < 1 creatinine level/year. Among patients with CrCl ≤ 50, 27.1% received < 2 creatinine levels/year. Baseline renal dysfunction was associated with a higher likelihood of insufficient creatinine monitoring (adjusted odds ratio 3.64, 95% confidence interval 1.81–7.29). This shows a significant gap in the monitoring of patients on DOACs—patients with renal impairment are already at higher risk for adverse events. Future studies are needed to describe the barriers in monitoring these patients and to identify how to optimally address them.